Supportive Care

Intensity-modulated radiation therapy (IMRT) improved survival and reduced toxicities compared with conventional radiation treatment in patients with head and neck cancer, according to a recent database analysis.

Traditionally, palliative care for patients with cancer is geared towards end-of-life measures, but a new study from the Princess Margaret Cancer Center in Toronto suggests patients who receive palliative care earlier in their cancer therapy report improved quality of life and greater satisfaction.

Eltrombopag has received a Breakthrough Therapy designation from the FDA for the treatment of cytopenias in patients with severe aplastic anemia who have had insufficient response to immunosuppressive therapy.

So many new agents for the treatment of men with castration-resistant prostate cancer (CRPC) have been introduced in the past several years that optimal sequencing of therapies remains an unsettled question.

Ayalew Tefferi, MD, hematologist, Mayo Clinic, Rochester, Minnesota, discusses the toxicity of imetelstat in patients with myelofibrosis.

Men who experience hot flashes because they are undergoing androgen-deprivation therapy for prostate cancer are not significantly helped by two treatments that alleviate that symptom in menopausal women, the results of a study show.

Both men and women report a significant decline in sexual satisfaction after hematopoietic cell transplantation that is sustained at 3-year follow-up.

It's been well established now that cancer survivorship begins on the day of diagnosis. Despite the positive spin that this presents for patients, families, friends, and coworkers, most people still associate cancer survivorship with completing treatment and getting on with life.

The phase III EPIC trial that was exploring ponatinib in untreated patients with chronic myeloid leukemia has been discontinued following a high occurrence of arterial thrombotic events.

A meta-analysis of nearly 2000 patients has shown that physical activity may substantially reduce the risk of developing esophageal cancer, especially esophageal adenocarcinoma.

The second installment from our roundtable with oncology nursing experts discussing some of the key challenges in oncology nursing today.

Julie R. Brahmer, MD, from Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, discusses the management of adverse events (AEs) from treatment with immunotherapies.

Researchers find that patients are not referred for supportive care services.

Alex A. Adjei, MD, PhD, Professor and Chair, Department of Medicine, Katherine Anne Gioia Chair in Cancer Medicine, Senior Vice President, Clinical Research, Roswell Park Cancer Institute, discusses eye toxicity from MEK inhibitors.

A multisite, randomized, double-blind trial evaluating the fatigue-ameliorating properties of American ginseng in cancer patients and recent survivors has found the herb to be helpful in reducing some aspects of CRF, with the benefit strongest among patients currently in treatment.

Two teams of investigators report that analysis of germline polymorphisms yields valuable clues about which patients may experience adverse events from anticancer therapies.

Adverse events associated with ipilimumab for the treatment of metastatic melanoma are better understood after further analysis of clinical trial data that led to the FDA's 2011 approval of the drug.